浜崎敬文

Hamasaki Yoshifumi

競争的資金等の研究課題 (3件)：

論文 (70件)：

Midori Sakashita, Yoshifumi Hamasaki, Rikako Oki, Yohei Komaru, Yoshihisa Miyamoto, Teruhiko Yoshida, Ryo Matsuura, Kent Doi, Masaomi Nangaku. Serum myostatin at dialysis initiation may predict 1-year mortality and hospitalization. Nephron. 2024
Kohei Yoshimoto, Ryo Matsuura, Yohei Komaru, Teruhiko Yoshida, Yoshihisa Miyamoto, Yoshifumi Hamasaki, Ryota Inokuchi, Masaomi Nangaku, Kent Doi. Solute Clearance Evaluation and Filter Clotting Prediction in Continuous Renal Replacement Therapy. Journal of clinical medicine. 2023. 12. 24
Teruhiko Yoshida, Ryo Matsuura, Yohei Komaru, Yoshihisa Miyamoto, Kohei Yoshimoto, Yoshifumi Hamasaki, Eisei Noiri, Masaomi Nangaku, Kent Doi. Different Roles of Functional and Structural Renal Markers Measured at Discontinuation of Renal Replacement Therapy for Acute Kidney Injury. Blood purification. 2023. 1-7
Ryo Matsuura, Yohei Komaru, Yoshifumi Hamasaki, Masaomi Nangaku, Kent Doi. Benefit of higher blood pressure target in severe acute kidney injury (AKI) treated by continuous renal replacement therapy (CRRT). Shock (Augusta, Ga.). 2023
Yohei Komaru, Rei Isshiki, Ryo Matsuura, Yoshifumi Hamasaki, Masaomi Nangaku, Kent Doi. Application of urinary biomarkers for diagnosing acute kidney injury in critically ill patients without baseline renal function data. Journal of critical care. 2023. 77. 154312-154312

MISC (1件)：

Yoshifumi Hamasaki, Koji Okamoto, Kent Doi, Toshiro Fujita, Eisei Noiri. Simvastatin ameliorates renal fibrosis via suppressing uterine sensitization-associated gene-1 (USAG-1), a BMP-7 antagonist, in mouse adenine-induced tubulointerstitial injury model. FASEB JOURNAL. 2010. 24

※　J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。登録・更新については、こちらをご覧ください。

浜崎 敬文